Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 16, 2017. The document serves as a transaction notification reporting changes in the notional interest of Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. The transactions occurred on October 12, 2017, involving the re-investment of dividends paid on that date into the Company's 2009 Deferred Annual Bonus Plan.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics for the Company. It exclusively details specific share transactions for individual executives. The following transaction metrics were reported:
- Instrument Types: Ordinary Shares (ISIN: GB0009252882) and American Depositary Shares (ADSs) (ISIN: US37733W1053).
- Transaction Price (Ordinary Shares): £15.275 per share.
- Transaction Price (ADSs): $41.020 per ADS.
- Transaction Nature: Increase in notional interest via dividend re-investment (personal contributions and matching shares).
Material Changes Versus Prior Period
The filing does not provide comparative financial data or material changes in the Company's business operations versus prior periods. The only changes reported are the incremental increases in shareholdings for the listed executives resulting from the October 12, 2017 dividend re-investment.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, risk factors, or contingencies. It is a statutory disclosure of insider trading activity compliant with Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Important Facts for Investor Verification
- Executive Participation: Ten senior executives participated in the dividend re-investment plan, including CEO Emma Walmsley, CFO Simon Dingemans, and President of R&D Peter Vallance.
- Transaction Volume: Aggregated volumes varied by executive, with CFO Simon Dingemans reporting the highest volume of Ordinary Shares (2,151.842) and SVP & General Counsel David Troy reporting the highest volume of ADSs (884.644).
- Share Class Distinction: Most executives transacted in Ordinary Shares, while CEO of GSK Consumer Healthcare (Brian McNamara) and SVP & General Counsel (David Troy) transacted in ADSs.
- Plan Details: All transactions were executed under the 2009 Deferred Annual Bonus Plan, involving both personal contributions and company matching shares.